The Ruesch Center for the Cure of Gastrointestinal Cancers

March 19th, 2020

“The approval of nivolumab and ipilimumab in the second-line treatment of advanced HCC means we will have a combination immune therapy option in patients who have progressed on frontline therapy. The overall survival (OS) of nivolumab and ipilimumab in the second-line treatment of advanced HCC as shown in CheckMate-040 was very promising, so far the longest duration of OS in the second-line setting for advanced-stage HCC, tested in clinical trials,” said Aiwu Ruth He, MD, PhD, associate professor of Medical Oncology at Georgetown University.

February 6th, 2020

Benjamin Weinberg, MD, assistant professor of medicine and attending physician at MedStar Georgetown University Hospital, Washington, DC, discusses novel agents that may impact the treatment landscape for colorectal cancer (CRC) once made available in the community setting.

January 6th, 2020

In August of 2016, Dan Hilton arrived at MedStar Georgetown University Hospital to be evaluated for a liver transplant. He had been diagnosed with cirrhosis, the result of a hepatitis C infection contracted many years earlier. After multiple tests, he received unexpected news; the doctors found tumors on his liver.